Sunday, December 03, 2017 4:42:32 PM
It has always been said that the insider stock sales have followed a 10b5-1 stock trading plan which is the right way to do it.
Considering the Orencia Failure was announced the morning of the Q3 17' earning call and the Necuparanib Failure was announced the morning of the Q2 16' earnings call it would seem that Momenta releases its info at will.
It also means trading under a 10b5-1 is moot.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM